2016 Diabetes Heart Failure 
Cardiovascular Diabetology
AUGUST 6, 2024
Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included.
European Journal of Heart Failure
FEBRUARY 25, 2025
Sodiumglucose cotransporter 2 (SGLT2) inhibitors in acute heart failure. Aims Results from randomized trials suggest benefit of sodiumglucose cotransporter 2 (SGLT2) inhibitor initiation in clinically stable acute heart failure.
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Type 2 Diabetes Mellitus (T2DM) is a rapidly growing global health problem with increasing prevalence. from 2016‐2019 and secondary diagnosis of T2DM. from 2016‐2019 and secondary diagnosis of T2DM. Of those patients, 35.43% (n=273,993) were diabetic and 64.57% (n=151,112) were non‐diabetic.
Circulation: Heart Failure
MARCH 8, 2024
Circulation: Heart Failure, Ahead of Print. Background:Current prevalence estimates of heart failure (HF) are primarily based on self-report or HF hospitalizations. Results:Median age was 73 (25th–75th percentile 67–81) years, 53.2% were female, 25.6% were Black, 12.8% were Chinese, and 40.0% were White. were female, 25.6%
Stroke Journal
FEBRUARY 1, 2024
Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE. Patients were identified to have diabetes as derived by the Charlson Comorbidity Index ICD 10 codes E10 through E14.
Circulation
NOVEMBER 11, 2024
This study evaluates the outcomes in patients admitted for HF with and without hyperkalemia.Methods:We used the Nationwide Readmissions Database (NRD) from 2016-2019, extracting adult patients with a primary diagnosis of HF who were admitted between January and November of each year. Survey procedures were applied using SAS 9.4.Results:We
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
x) from 2016‐2019. The rate of 30‐day readmission was overall stable (7.34% in 2016 and 7.70% in 2019; p=0.42), but the 90‐day readmission rate slightly increased from 11.69% in 2016 to 12.47% in 2019 (p=0.04). ConclusionThe annual rate of 90‐day readmission, but not 30‐day readmission, increased from 2016 to 2019.
Expert insights. Personalized for you.
98 
Let's personalize your content